Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 01, 2022 07:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

-- Preparations continue for U.S. commercial launch in June 2022 in BBS and Alström syndrome, pending FDA approval -- -- First commercial sales of IMCIVREE in Germany and France expected in 2Q2022 – ...
February 24, 2022 08:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome

-- FDA sets updated PDUFA goal date of June 16, 2022 -- -- Company also announces withdrawal of proposed Alström syndrome indication from Type II variation application under review by the EMA -- ...
February 23, 2022 08:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces Promotions within its Executive Leadership Team

BOSTON, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare...
February 22, 2022 08:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on Tuesday, March 1, 2022

BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare...
February 16, 2022 08:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces Positive Interim Data from Long-term Extension Study of Setmelanotide in Bardet-Biedl Syndrome (BBS)

-- Patients with BBS achieved deepened and sustained weight loss at 24 months on setmelanotide therapy -- -- Company to provide update on U.S. BBS commercial readiness during virtual event today at 4...
February 08, 2022 16:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals to Host Virtual Bardet-Biedl Syndrome (BBS) Event on February 16

-- Key opinion leaders and patient caregiver to discuss patient experience -- -- Company to provide update on U.S. BBS commercial readiness during event for investors and analysts -- -- Prescription...
January 13, 2022 09:15 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces First Patients Dosed in DAYBREAK and Weekly Trials Evaluating Setmelanotide for Rare Genetic Diseases of Obesity

-- DAYBREAK is the most comprehensive Phase 2 trial ever initiated in rare genetic diseases of obesity ---- DAYBREAK is evaluating setmelanotide in patients with severe obesity and hyperphagia caused...
December 06, 2021 08:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals and RareStone Ltd. Announce Exclusive Licensing Agreement for the Development and Commercialization of IMCIVREE (setmelanotide) in China

-- RareStone to seek marketing authorization for IMCIVREE to treat obesity due to biallelic POMC, PCSK1 and LEPR deficiencies and Bardet-Biedl and Alström syndromes in mainland China, Hong Kong and...
November 15, 2021 07:45 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome

BOSTON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic...
November 09, 2021 16:01 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals to Present at Stifel 2021 Virtual Healthcare Conference

BOSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic...